4D Molecular Therapeutics, Inc. (FDMT)
10.46
-0.33
(-3.06%)
USD |
NASDAQ |
Nov 18, 16:00
10.46
0.00 (0.00%)
After-Hours: 20:00
4D Molecular Therapeutics Enterprise Value : 321.10M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 321.10M |
| November 17, 2026 | 339.70M |
| November 16, 2026 | 367.89M |
| November 13, 2026 | 420.88M |
| November 12, 2026 | 414.40M |
| November 11, 2026 | 463.73M |
| November 10, 2026 | 433.85M |
| November 09, 2026 | 434.98M |
| November 06, 2026 | 422.01M |
| November 05, 2026 | 365.64M |
| November 04, 2026 | 423.70M |
| November 03, 2026 | 405.10M |
| November 02, 2026 | 372.40M |
| October 30, 2026 | 402.28M |
| October 29, 2026 | 451.89M |
| October 28, 2026 | 460.35M |
| October 27, 2026 | 405.66M |
| October 26, 2026 | 353.23M |
| October 23, 2026 | 340.27M |
| October 22, 2026 | 399.46M |
| October 21, 2026 | 442.87M |
| October 20, 2026 | 469.93M |
| October 19, 2026 | 424.27M |
| October 16, 2026 | 415.81M |
| October 15, 2026 | 456.96M |
| Date | Value |
|---|---|
| October 14, 2026 | 419.19M |
| October 13, 2026 | 428.21M |
| October 12, 2026 | 464.29M |
| October 09, 2026 | 482.90M |
| October 08, 2026 | 447.38M |
| October 07, 2026 | 441.18M |
| October 06, 2026 | 439.49M |
| October 05, 2026 | 459.78M |
| October 02, 2026 | 502.06M |
| October 01, 2026 | 511.65M |
| September 30, 2026 | 538.14M |
| September 29, 2026 | 477.94M |
| September 28, 2026 | 481.80M |
| September 25, 2026 | 476.83M |
| September 24, 2026 | 490.08M |
| September 23, 2026 | 506.09M |
| September 22, 2026 | 554.68M |
| September 21, 2026 | 519.35M |
| September 18, 2026 | 518.24M |
| September 17, 2026 | 488.43M |
| September 16, 2026 | 437.63M |
| September 15, 2026 | 430.45M |
| September 14, 2026 | 437.63M |
| September 11, 2026 | 405.05M |
| September 10, 2026 | 422.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 473.01M |
| Amgen, Inc. | 280.92B |
| Anika Therapeutics, Inc. | 163.62M |
| BioCryst Pharmaceuticals, Inc. | 2.322B |
| Imunon, Inc. | 6.500M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.06M |
| Revenue (Quarterly) | 4.145M |
| Total Expenses (Quarterly) | 82.20M |
| EPS Diluted (Quarterly) | -1.080 |
| Gross Profit Margin (Quarterly) | 51.63% |
| Profit Margin (Quarterly) | -1.88K% |
| Earnings Yield | -26.69% |
| Normalized Earnings Yield | -26.69 |